| Norway to buy Biogen's Spinraza medicine: broadcaster NRK |  | | OSLO (Reuters) - Norwegian authorities will buy the rare-disease treatment Spinraza for patients from U.S. drugmaker Biogen Inc at a cost of 7 million Norwegian crowns ($880,381.33) per year per patient, public broadcaster NRK reported on Monday. | |  | | OxyContin maker stops promoting opioids, cuts sales staff |  | | (Reuters) - OxyContin maker Purdue Pharma LP said on Saturday that it has cut its sales force in half and will stop promoting opioids to physicians, following widespread criticism of the ways that drugmakers market addictive painkillers. | |  | | Hand-me-down plastic toys may not be good for kids |  | | (Reuters Health) - Children who play with second-hand plastic toys may be exposed to unsafe levels of chemicals like lead and cadmium that have been linked to developmental problems and organ damage, a UK study suggests. | |  | |  |  |  |  | Related Video | |  | | |  | | |  |  |  |  |  | | A quick-fix on the day's news delivered when you want it. Register Today |  | |  |  |  | | A daily digest of breaking business news, coverage of the US economy, major corporate news and the financial markets. Register Today |  | |  | | » » MORE NEWSLETTERS |  | |